Publications by authors named "A P Riviera"
Background: Risk scores (RS) evaluate the likelihood of short-term mortality in patients diagnosed with community-acquired pneumonia (CAP). However, there is a scarcity of evidence to determine the risk of long-term mortality. This article aims to compare the effectiveness of 16 scores in predicting mortality at three, six, and twelve months in adult patients with CAP.
View Article and Find Full Text PDFArticle Synopsis
- The paper outlines new Italian guidelines for testing autoantibodies in patients with myasthenia gravis, created through a consensus process involving surveys, online discussions, and workshops.
- It provides important clinical information about myasthenic syndromes, including when to test for antibodies and the limitations of such tests.
- Additionally, the guidelines include instructions for interpreting results and a standardized laboratory protocol to aid neurologists and clinical pathologists.
Background: The recent literature suggests that the incidence and prevalence of myasthenia gravis (MG) are changing. We performed a population-based study of MG in the province of Trentino (524,826 inhabitants) and compared the results with those collected 20 years ago.
Methods: Multiple sources of information (discharge diagnosis, antibody tests and anticholinesterase drugs) were analyzed.
Article Synopsis
- Bone marrow mesenchymal stromal cells (BM-MSCs) can thrive alongside cancer cells and can be engineered to deliver therapeutic genes, making them a promising vehicle for cancer treatment.
- In a study using a mouse model of plasmacytoma, engineered BM-MSCs carrying the interferon-alpha (IFN-α) gene successfully slowed tumor growth and increased the survival rate of the mice when administered subcutaneously.
- However, intravenous administration of these engineered cells was less effective due to their accumulation in the lungs, indicating that the delivery method needs refinement for better outcomes in treating multiple myeloma.
De novo expression of B7-1 impaired tumorigenicity of TRAMP-C2 mouse prostate adenocarcinoma (TRAMP-C2/B7), but it did not elicit a protective response against TRAMP-C2 parental tumor, unless after in vitro treatment with IFN-gamma. TRAMP-C2 cells secrete TGF-beta and show low MHC-I expression. Treatment with IFN-gamma increased MHC-I expression by induction of some APM components and antagonizing the immunosuppressant activity of TGF-beta.
View Article and Find Full Text PDF